open access

Vol 13, No 6 (2017)
Review paper
Published online: 2018-01-04
Get Citation

Management of dermatological adverse events during nivolumab treatment

Monika Słowińska, Aldona Maciąg, Natalia Rozmus, Elwira Paluchowska, Witold Owczarek
DOI: 10.5603/OCP.2017.0033
·
Oncol Clin Pract 2017;13(6):301-307.

open access

Vol 13, No 6 (2017)
REVIEW ARTICLES
Published online: 2018-01-04

Abstract

Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of advanced and metastatic melanoma, as well as in kidney, bladder, and non-small cell lung carcinomas. Adverse events of PD-1 inhibitors result mostly from autoimmune mechanisms, include gastrointestinal inflammatory diseases, hepatotoxicity, neurotoxicity, endocrinopathies, and skin toxicities. In this article, we highlight the main cutaneous adverse events associated with PD-1 inhibitors and provide a set of practical guidelines about their management. Additionally, we report a case of nivolumab-induced bullous pemphigoid in a patient with metastatic melanoma.

Abstract

Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of advanced and metastatic melanoma, as well as in kidney, bladder, and non-small cell lung carcinomas. Adverse events of PD-1 inhibitors result mostly from autoimmune mechanisms, include gastrointestinal inflammatory diseases, hepatotoxicity, neurotoxicity, endocrinopathies, and skin toxicities. In this article, we highlight the main cutaneous adverse events associated with PD-1 inhibitors and provide a set of practical guidelines about their management. Additionally, we report a case of nivolumab-induced bullous pemphigoid in a patient with metastatic melanoma.
Get Citation

Keywords

nivolumab, PD-1 inhibitors, cutaneous adverse events

About this article
Title

Management of dermatological adverse events during nivolumab treatment

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 6 (2017)

Article type

Review paper

Pages

301-307

Published online

2018-01-04

DOI

10.5603/OCP.2017.0033

Bibliographic record

Oncol Clin Pract 2017;13(6):301-307.

Keywords

nivolumab
PD-1 inhibitors
cutaneous adverse events

Authors

Monika Słowińska
Aldona Maciąg
Natalia Rozmus
Elwira Paluchowska
Witold Owczarek

References (23)
  1. Grzywnowicz M, Giannopoulos K. Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. Acta Haematologica Polonica. 2012; 43(2): 132–145.
  2. Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016; 4: 70.
  3. Stevenson ML, Wang CQF, Abikhair M, et al. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatol. 2017; 153(4): 299–303.
  4. Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010; 146(12): 1382–1388.
  5. Opdivo. Chatakterystyka produktu leczniczego. https://ec.europa.eu/health/documents/community-register/2015/20150619132099/anx_132099_pl.pdf.
  6. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44: 51–60.
  7. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60: 190–209.
  8. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute May 28, 2009 (v4.03: June 14, 2010).
  9. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016; 60: 12–25.
  10. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol. 2016; 74(3): 455–61.e1.
  11. Hauschild A, Eichstaedt J, Möbus L, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017; 77: 84–87.
  12. Nayar N, Briscoe K, Fernandez Penas P. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma. J Immunother. 2016; 39(3): 149–152.
  13. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017; 76(1): 43–50.
  14. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2): 368–376.
  15. de Golian E, Kwong BY, Swetter SM, et al. Cutaneous Complications of Targeted Melanoma Therapy. Curr Treat Options Oncol. 2016; 17(11): 57.
  16. Weber JS, Postow M, Lao CD, et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist. 2016; 21(10): 1230–1240.
  17. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res. 2016; 4(5): 383–389.
  18. Lacouture M. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients. Wiley-Blackwell, New York 2014.
  19. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015; 4(5): 560–575.
  20. Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015; 3(1): 18–22.
  21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443–2454.
  22. Saniklidou AH, Tighe PJ, Fairclough LC, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res. 2017 [Epub ahead of print].
  23. Atzmony L, Mimouni I, Reiter O, et al. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J Am Acad Dermatol. 2017; 77(4): 691–699.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl